Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Apr 19, 2024
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with acute T cell lymphoblastic leukemia (T-ALL). The researchers want to find out if combining a type of stem cell transplant called haploidentical hematopoietic cell transplantation (haplo-HCT) with an unrelated cord blood unit (haplo-cord HCT) can help reduce the chances of the cancer returning. They will also look at how safe this combined treatment is for patients. The trial will compare the two methods to see which one works better for treating T-ALL.
To be eligible for the study, participants must have T-ALL and a suitable haploidentical donor for the transplant. They also need to be willing to undergo the procedure and be able to follow study guidelines. Patients will receive the cord blood infusion on the same day as their stem cell transplant. This trial is currently recruiting participants of all ages and genders. If you or a loved one is interested, it's important to discuss this option with a healthcare provider to see if it might be a good fit.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with acute T cell lymphoblastic leukemia
- • With available minimal residual disease parameters assessed by flow cytometry and/or quantitative polymerase chain reaction
- • Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor
- • With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
- • Signing an informed consent form, having the ability to comply with study and follow-up procedures
- Exclusion Criteria:
- • With other malignancies
- • Failing to acquire a suitable unrelated cord blood unit
- • With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy
- • With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation
- • With severe organ dysfunction
- • In pregnancy or lactation period
- • With any conditions not suitable for the trial (investigators' decision)
About The First Affiliated Hospital Of Soochow University
The First Affiliated Hospital of Soochow University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical disciplines to facilitate high-quality, ethically conducted studies that aim to enhance treatment options and improve patient outcomes. With a commitment to collaboration and scientific rigor, the institution plays a pivotal role in contributing to the global body of medical knowledge while ensuring the highest standards of patient care and safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suzhou, Jiangsu, China
Suzhou, Jiangsu, China
Patients applied
Trial Officials
Yang XU
Principal Investigator
The First Affiliated Hospital of Soochow University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported